CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions
Acute Lymphoblastic Leukemia, in Relapse
Interventions
DRUG

Bortezomib Injection

Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;

DRUG

rituximab injection

Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)

Trial Locations (1)

852

Hong Kong Children's Hospital, Hong Kong

All Listed Sponsors
collaborator

Shanghai Children's Medical Center

OTHER

lead

Chinese University of Hong Kong

OTHER

NCT04224571 - CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children | Biotech Hunter | Biotech Hunter